LSCN Ltd. and the Technology Commercialization Group (TCG) have created an international strategic partnership to help life science companies with transatlantic business development and corporate development projects.
“We’re delighted to be working with LSCN, a premier European life sciences consulting firm”, said Ken West, Managing Partner of TCG.
West continued, “They have the skills, local experience and ‘on-the-ground’ presence necessary to help our US-based clients develop and implement European market entry and growth strategies”.
The US and Europe are the two largest life science, medical device, biotech and pharmaceutical markets in the world, but they have vastly different regulatory, reimbursement, marketing and legal environments.
Life science companies who have developed and marketed a product on one continent often find that developing business across the Atlantic is a challenge. This is especially true for emerging and mid-sized companies.
Dr. Alrik Koppenhöfer, Managing Director & Partner of LSCN, commented “Many European companies aim to internationalize their business, especially in the US marketplace, but are concerned about the FDA, US lawyers and the resources necessary to effectively compete. TCG has guided many European companies in entering or expanding in the US, so they know what works well. Vice versa, LSCN supports many companies in Europe’s multi-cultural and diverse legal and business environment to implement customized solutions”.
In addition to providing services for transatlantic corporate development and growth, both LSCN and TCG provide specialized life science product development oversight as well as interim management for corporate expansion efforts.